The Impact of Obesity on the Resolution of Hypertension Following Adrenalectomy for Primary Hyperaldosteronism.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
accepted:
08
04
2023
medline:
1
8
2023
pubmed:
15
7
2023
entrez:
14
7
2023
Statut:
ppublish
Résumé
This study aims to determine the impact of patient obesity on the resolution of hypertension and pill burden post-adrenalectomy for PA. Primary hyperaldosteronism (PA) is the most common cause of secondary hypertension that may be remedied with surgery (unilateral adrenalectomy). Obesity may independently cause hypertension through several mechanisms including activation of the renin-angiotensin-aldosterone pathway. The influence of obesity on the efficacy of adrenalectomy in PA has not been established. This is a retrospective analysis of prospectively collected data on patients undergoing adrenalectomy for PA at a single, tertiary-care surgical centre from January 2015 to December 2020. Electronic health records of patients were screened to collect relevant data. The primary outcomes of the study include post-operative blood pressure, the reduction in the number of anti-hypertensive medications and potassium supplementation burden post-adrenalectomy. Fifty-three patients were included in the final analysis. There was a significant reduction in the blood pressure and the number of anti-hypertensive medications in all patients after adrenalectomy (p < 0.001). Of the 34 patients (64.2%) with pre-operative hypokalaemia, all became normokalaemic and were able to stop supplementation. However obese patients required more anti-hypertensive medications to achieve an acceptable blood pressure than overweight or normal BMI patients (p < 0.01). Multivariate logistic regression analysis showed that male gender and BMI were independent predictors of resolution of hypertension (p <0.01). Unilateral adrenalectomy improves the management of hypertension and hypokalaemia when present in patients with PA. However, obesity has an independent deleterious impact on improvement in blood pressure post-adrenalectomy for PA.
Sections du résumé
BACKGROUND
This study aims to determine the impact of patient obesity on the resolution of hypertension and pill burden post-adrenalectomy for PA. Primary hyperaldosteronism (PA) is the most common cause of secondary hypertension that may be remedied with surgery (unilateral adrenalectomy). Obesity may independently cause hypertension through several mechanisms including activation of the renin-angiotensin-aldosterone pathway. The influence of obesity on the efficacy of adrenalectomy in PA has not been established.
METHODS
This is a retrospective analysis of prospectively collected data on patients undergoing adrenalectomy for PA at a single, tertiary-care surgical centre from January 2015 to December 2020. Electronic health records of patients were screened to collect relevant data. The primary outcomes of the study include post-operative blood pressure, the reduction in the number of anti-hypertensive medications and potassium supplementation burden post-adrenalectomy.
RESULTS
Fifty-three patients were included in the final analysis. There was a significant reduction in the blood pressure and the number of anti-hypertensive medications in all patients after adrenalectomy (p < 0.001). Of the 34 patients (64.2%) with pre-operative hypokalaemia, all became normokalaemic and were able to stop supplementation. However obese patients required more anti-hypertensive medications to achieve an acceptable blood pressure than overweight or normal BMI patients (p < 0.01). Multivariate logistic regression analysis showed that male gender and BMI were independent predictors of resolution of hypertension (p <0.01).
CONCLUSION
Unilateral adrenalectomy improves the management of hypertension and hypokalaemia when present in patients with PA. However, obesity has an independent deleterious impact on improvement in blood pressure post-adrenalectomy for PA.
Identifiants
pubmed: 37452142
doi: 10.1007/s00268-023-07021-5
pii: 10.1007/s00268-023-07021-5
pmc: PMC10387460
doi:
Substances chimiques
Antihypertensive Agents
0
Aldosterone
4964P6T9RB
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2188-2196Informations de copyright
© 2023. The Author(s).
Références
J Lab Clin Med. 1955 Jan;45(1):3-17
pubmed: 13233623
Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699
pubmed: 28576687
Hypertens Res. 2017 Dec;40(12):988-993
pubmed: 28978983
J Hypertens. 2008 Sep;26(9):1816-23
pubmed: 18698217
Lancet. 2008 Jun 7;371(9628):1921-6
pubmed: 18539224
Ann Surg. 2020 Dec;272(6):1125-1132
pubmed: 30672800
J Intern Med. 2013 Mar;273(3):219-34
pubmed: 23163728
FASEB J. 2008 May;22(5):1502-11
pubmed: 18171693
Am J Hypertens. 1994 Oct;7(10 Pt 1):886-93
pubmed: 7826551
Surgery. 2012 Mar;151(3):437-43
pubmed: 22000827
J Hum Hypertens. 2011 Sep;25(9):532-8
pubmed: 20927128
Ann Surg. 2008 Mar;247(3):511-8
pubmed: 18376197
Horm Metab Res. 2020 Jun;52(6):454-458
pubmed: 32252109
J Clin Endocrinol Metab. 2008 Jul;93(7):2566-71
pubmed: 18445663
Lancet Diabetes Endocrinol. 2017 Mar;5(3):174-183
pubmed: 28065734
Int Urol Nephrol. 2017 Dec;49(12):2151-2156
pubmed: 28918446
Br J Surg. 2015 Mar;102(4):307-17
pubmed: 25605481
Nat Rev Dis Primers. 2017 Jun 15;3:17034
pubmed: 28617414
Hypertension. 2008 May;51(5):1366-71
pubmed: 18347224
Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50
pubmed: 29129575
Ann Intern Med. 2001 Aug 21;135(4):258-61
pubmed: 11511140
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
Blood Press. 2018 Dec;27(6):314-340
pubmed: 30380928
World J Surg. 2005 Feb;29(2):155-9
pubmed: 15650803